LONDON, Sept. 28, 2015 /PRNewswire/ -- Smith &
Nephew (NYSE:SNN;LSE:SN), the global, medical technology business,
today announced the launch of its new NASASTENT Dissolvable Nasal
Dressing, a structural intranasal splint used to minimize bleeding
and prevent post-op adhesions after sinus
surgery.
Made from a plant-based material known as CarboxyMethyl
Cellulose (CMC), the NASASTENT dressing can be easily customized by
simply trimming it to fit the size needs of each patient and offers
tapered edges for ease of placement into the nasal cavity. Once in
place, the soft dressing quickly regains its shape as it conforms
to the patient's anatomy; providing sufficient pressure to minimize
bleeding and hold the surrounding soft tissues in place as they
heal. Recent testing shows that the NASASTENT dressing's
compressive strength is six-times greater than its leading
competitor and provides significantly higher tissue separation
force over a variety of simulated nasal cavity gaps ranging from 7
to 10mm.i
Also, unlike other structural dressings which break down into
fragments that must be later removed by a physician, the CMC used
in the NASASTENT dressing converts into a hydrocolloidal gel after
absorbing sufficient nasal fluid and simply drains from the cavity
as part of the natural outflow. CMC has a well-documented clinical
history with over two decades of use in the
pharmaceuticalii and medical deviceiii
industries. The NASASTENT dressing is capable of absorbing up to
16-times its dry weight in fluid and does not require any special
storage conditionsiv.
"Smith & Nephew is committed to innovation that improves
both the patient and the physician experience and is proud to offer
pioneering technologies such as NASASTENT within our leading
specialist ENT surgical portfolio," said Mira Sahney, General Manager for ENT and
Gynecology.
Surgeons attending the annual American Academy of
Otolaryngology Surgeons (AAO) meeting this week in
Dallas will be able to learn more
about the NASASTENT Dissolvable Nasal Dressing at the Smith &
Nephew booth #1721.
About Smith & Nephew
Smith & Nephew is a global medical technology business
dedicated to helping healthcare professionals improve people's
lives. With leadership positions in Orthopaedic Reconstruction,
Advanced Wound Management, Sports Medicine and Trauma &
Extremities, Smith & Nephew has around 14,000 employees and a
presence in more than 100 countries. Annual sales in 2014 were more
than $4.6 billion. Smith & Nephew
is a member of the FTSE100 (LSE: SN, NYSE: SNN).
For more information about Smith & Nephew, please visit our
corporate website www.smith-nephew.com, follow @SmithNephewplc on
Twitter or visit SmithNephewplc on Facebook.com
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls; litigation relating to patent or other claims;
legal compliance risks and related investigative, remedial or
enforcement actions; strategic actions, including acquisitions and
dispositions, our success in performing due diligence, valuing and
integrating acquired businesses; disruption that may result from
transactions or other changes we make in our business plans or
organisation to adapt to market developments; and numerous other
matters that affect us or our markets, including those of a
political, economic, business, competitive or reputational nature.
Please refer to the documents that Smith & Nephew has filed
with the U.S. Securities and Exchange Commission under the U.S.
Securities Exchange Act of 1934, as amended, including Smith &
Nephew's most recent annual report on Form 20-F, for a discussion
of certain of these factors. Any forward-looking statement is based
on information available to Smith & Nephew as of the date of
the statement. All written or oral forward-looking statements
attributable to Smith & Nephew are qualified by this caution.
Smith & Nephew does not undertake any obligation to update or
revise any forward-looking statement to reflect any change in
circumstances or in Smith & Nephew's expectations.
™Trademark of Smith & Nephew. Registered US
Patent and Trademark Office.
i P/N 67244
ii The use of micronized cellulose disintegrants as
insoluble swellable matrices for sustained-release tablets.
Nakagami H, Nada M. Drug Des Deliv. 1991 Jul;7(4):321-32.
iii Reduction of adhesions after uterine myomectomy
by Seprafilm membrane (HAL-F): a blinded, prospective, randomized,
multicenter clinical study. Seprafilm Adhesion Study Group. Diamond
MP. Fertil Steril. 1996 Dec; 66(6):904-10.
iv P/N 67130
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/new-customizable-nasastent-nasal-dressing-from-smith--nephew-designed-to-dissolve-completely-300149501.html
SOURCE Smith & Nephew